Benchmark Has Lowered Expectations for Milestone Scientific (NYSE:MLSS) Stock Price

Milestone Scientific (NYSE:MLSS) had its price target decreased by analysts at Benchmark from $1.25 to $1.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “speculative buy” rating on the stock. Benchmark’s target price points to a potential upside of 228.95% from the stock’s previous close.

Milestone Scientific Stock Down 0.6%

Shares of MLSS opened at $0.30 on Thursday. The firm has a market cap of $23.90 million, a price-to-earnings ratio of -4.34 and a beta of 0.92. The company’s fifty day moving average is $0.44 and its 200-day moving average is $0.63. Milestone Scientific has a 12 month low of $0.28 and a 12 month high of $1.39.

Insiders Place Their Bets

In other Milestone Scientific news, major shareholder S.R.L. Bp4 sold 100,000 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $0.44, for a total value of $44,000.00. Following the completion of the sale, the insider owned 8,896,765 shares of the company’s stock, valued at $3,914,576.60. The trade was a 1.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 377,829 shares of company stock worth $173,739 in the last 90 days. 12.51% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Brookwood Investment Group LLC acquired a new stake in Milestone Scientific in the 1st quarter worth approximately $46,000. XTX Topco Ltd grew its holdings in Milestone Scientific by 99.2% during the first quarter. XTX Topco Ltd now owns 34,135 shares of the company’s stock valued at $32,000 after purchasing an additional 17,002 shares during the last quarter. Carnegie Investment Counsel bought a new position in shares of Milestone Scientific in the second quarter valued at approximately $105,000. Finally, Raymond James Financial Inc. lifted its stake in shares of Milestone Scientific by 416.7% in the second quarter. Raymond James Financial Inc. now owns 62,000 shares of the company’s stock worth $39,000 after buying an additional 50,000 shares during the last quarter. 5.79% of the stock is owned by institutional investors.

Milestone Scientific Company Profile

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.